|
HUE040467T2
(hu)
*
|
2007-04-03 |
2019-03-28 |
Amgen Res Munich Gmbh |
Keresztfaj-specifikus kötõdomén
|
|
US10981998B2
(en)
*
|
2008-10-01 |
2021-04-20 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
JP6126782B2
(ja)
*
|
2008-10-01 |
2017-05-10 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
|
|
EA201290020A1
(ru)
|
2009-05-19 |
2013-10-30 |
ЭйАйСи БЛЭБ КОМПАНИ |
Композитный токоприемник и способы его изготовления
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
KR102447595B1
(ko)
|
2010-11-30 |
2022-09-26 |
추가이 세이야쿠 가부시키가이샤 |
세포상해 유도 치료제
|
|
CN103687872A
(zh)
|
2011-04-22 |
2014-03-26 |
新兴产品开发西雅图有限公司 |
前列腺特异性膜抗原结合蛋白和相关组合物以及方法
|
|
EP2710042A2
(en)
*
|
2011-05-16 |
2014-03-26 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
KR101870555B1
(ko)
|
2011-08-23 |
2018-06-22 |
로슈 글리카트 아게 |
T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
CA2864177C
(en)
|
2012-03-01 |
2019-11-26 |
Amgen Research (Munich) Gmbh |
Prolonged half-life albumin-binding protein fused bispecific antibodies
|
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
HK1215950A1
(zh)
*
|
2012-09-25 |
2016-09-30 |
艾科诺斯科技股份有限公司 |
异源二聚免疫球蛋白的纯化
|
|
CN104780940B
(zh)
|
2012-11-06 |
2017-11-07 |
拜耳制药股份公司 |
用于双特异性t细胞衔接体(bites)的制剂
|
|
CN103087171B
(zh)
*
|
2012-12-24 |
2015-01-14 |
中国人民解放军第四军医大学 |
一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
CN104968682A
(zh)
|
2013-02-05 |
2015-10-07 |
英格玛布股份公司 |
针对CD3ε和BCMA的双特异性抗体
|
|
JO3529B1
(ar)
*
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
US9695245B2
(en)
|
2013-03-15 |
2017-07-04 |
Edimer Pharmaceuticals, Inc |
Anti-ectodysplasin antibodies
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
|
EP3424952A1
(en)
*
|
2013-03-15 |
2019-01-09 |
Amgen, Inc |
Heterodimeric bispecific antibodies
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
PT3406633T
(pt)
|
2013-07-25 |
2022-05-04 |
Cytomx Therapeutics Inc |
Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos
|
|
EA201691925A1
(ru)
|
2014-03-28 |
2017-06-30 |
Ксенкор, Инк. |
Биспецифические антитела, которые связываются с cd38 и cd3
|
|
CA2895659A1
(en)
|
2014-07-01 |
2016-01-01 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
CN107108738A
(zh)
|
2014-07-25 |
2017-08-29 |
西托姆克斯治疗公司 |
抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
|
|
SG11201704274QA
(en)
|
2014-11-26 |
2017-06-29 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
|
KR20240116967A
(ko)
|
2014-11-26 |
2024-07-30 |
젠코어 인코포레이티드 |
Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
KR20240104220A
(ko)
|
2015-01-23 |
2024-07-04 |
사노피 |
항-ｃｄ3 항체, 항-ｃｄ123 항체, 및 ｃｄ3 및/또는 ｃｄ123에 특이적으로 결합하는 이중특이적 항체
|
|
CA2976360A1
(en)
*
|
2015-02-11 |
2016-08-18 |
Aptevo Research And Development Llc |
Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
MX383614B
(es)
|
2015-05-21 |
2025-03-14 |
Harpoon Therapeutics Inc |
Proteinas de union triespecificas y metodos de uso.
|
|
EA201792581A1
(ru)
*
|
2015-05-29 |
2018-07-31 |
Амфивена Терапьютикс, Инк. |
Способы применения биспецифических cd33- и cd3- связывающих белков
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
PL3331910T3
(pl)
|
2015-08-03 |
2020-05-18 |
Engmab Sàrl |
Przeciwciała monoklonalne przeciwko ludzkiemu antygenowi dojrzewania limfocytów B (BCMA)
|
|
RS60755B1
(sr)
|
2015-08-17 |
2020-10-30 |
Janssen Pharmaceutica Nv |
Anti-bcma antitela, bispecifični antigen vezujući molekuli koji se vezuju za bcma i cd3, i njihove upotrebe
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
UA126278C2
(uk)
|
2015-09-21 |
2022-09-14 |
Аптево Рісьорч Енд Девелопмент Ллс |
Поліпептиди, які зв'язують cd3
|
|
CN105198992B
(zh)
*
|
2015-10-16 |
2018-07-13 |
中国人民解放军海军总医院 |
一种人源抗创伤弧菌溶血素蛋白(vvh)抗体的制备方法与应用
|
|
CR20180250A
(es)
|
2015-11-02 |
2018-10-01 |
Janssen Pharmaceutica Nv |
Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y uso de estas
|
|
AU2016365742A1
(en)
*
|
2015-12-07 |
2018-06-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
IL260920B
(en)
|
2016-02-03 |
2022-09-01 |
Amgen Res Munich Gmbh |
Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
|
|
CA3017776A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
|
WO2017201488A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
HUE068801T2
(hu)
|
2016-06-14 |
2025-01-28 |
Xencor Inc |
Bispecifikus kontrollpont-gátló antitestek
|
|
KR20230129583A
(ko)
|
2016-06-21 |
2023-09-08 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
TWI781108B
(zh)
|
2016-07-20 |
2022-10-21 |
比利時商健生藥品公司 |
抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
HRP20240767T1
(hr)
*
|
2016-09-14 |
2024-09-13 |
Teneoone, Inc. |
Cd3 vezujuća antitijela
|
|
KR102559732B1
(ko)
*
|
2016-09-21 |
2023-07-26 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd123 결합 단백질 그리고 관련된 조성물 및 방법
|
|
KR102562519B1
(ko)
|
2016-10-14 |
2023-08-02 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
|
|
EA201990787A1
(ru)
|
2016-11-02 |
2019-12-30 |
Энгмаб Сарл |
Биспецифичное антитело к всма и cd3 и иммунологическое лекарственное средство для комбинированного применения в лечении множественной миеломы
|
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
|
|
JP6812551B2
(ja)
|
2016-11-23 |
2021-01-13 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原結合タンパク質
|
|
KR102633423B1
(ko)
|
2016-12-21 |
2024-02-06 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
WO2018177371A1
(en)
*
|
2017-03-29 |
2018-10-04 |
Taipei Medical University |
Antigen-specific t cells and uses thereof
|
|
CN110891974B
(zh)
|
2017-05-12 |
2021-08-06 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
|
CA3067584A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
JP7240335B2
(ja)
|
2017-06-20 |
2023-03-15 |
テネオワン， インコーポレイテッド |
抗ｂｃｍａ重鎖のみ抗体
|
|
CA3065328C
(en)
|
2017-06-21 |
2023-08-15 |
Gilead Sciences, Inc. |
Multispecific antibodies that target hiv gp120 and cd3
|
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
|
KR102414120B1
(ko)
|
2017-08-03 |
2022-06-28 |
암젠 인크 |
인터류킨-21 뮤테인 및 치료 방법
|
|
EP4403175A3
(en)
|
2017-09-08 |
2024-10-02 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
SG11202001358RA
(en)
|
2017-09-21 |
2020-03-30 |
Wuxi Biologics Ireland Ltd |
Novel anti-cd3epsilon antibodies
|
|
US12486325B2
(en)
|
2017-09-21 |
2025-12-02 |
WuXi Biologics Ireland Limited |
Anti-CD3epsilon antibodies
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
PE20201183A1
(es)
|
2017-10-13 |
2020-11-03 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso
|
|
CN111247171A
(zh)
|
2017-10-14 |
2020-06-05 |
西托姆克斯治疗公司 |
抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
|
|
CN112272563A
(zh)
|
2017-11-08 |
2021-01-26 |
Xencor股份有限公司 |
使用新颖抗pd-1序列的双特异性和单特异性抗体
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US10426424B2
(en)
|
2017-11-21 |
2019-10-01 |
General Electric Company |
System and method for generating and performing imaging protocol simulations
|
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
PE20201171A1
(es)
|
2017-12-22 |
2020-10-28 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen a cd22
|
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
|
CR20200330A
(es)
|
2018-01-12 |
2020-12-23 |
Amgen Inc |
Anticuerpos anti-pd-1 y métodos de tratamiento
|
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
IL277863B1
(en)
|
2018-04-11 |
2025-10-01 |
Inhibrx Inc |
Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
|
|
KR20210010862A
(ko)
|
2018-04-18 |
2021-01-28 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
|
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
|
|
CN119192397A
(zh)
|
2018-05-14 |
2024-12-27 |
哈普恩治疗公司 |
用于条件性激活免疫球蛋白分子的结合部分
|
|
MY205856A
(en)
|
2018-05-16 |
2024-11-15 |
Stichting Vumc |
Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
|
|
JOP20190116A1
(ar)
|
2018-05-24 |
2019-11-24 |
Janssen Biotech Inc |
الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
|
|
CN112513085B
(zh)
|
2018-05-24 |
2024-06-18 |
詹森生物科技公司 |
Psma结合剂及其用途
|
|
MX2020012495A
(es)
|
2018-06-01 |
2021-02-15 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas.
|
|
US20210221908A1
(en)
|
2018-06-03 |
2021-07-22 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against ceacam5 and cd47
|
|
JP7651450B2
(ja)
|
2018-07-24 |
2025-03-26 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法
|
|
FI3830132T3
(fi)
|
2018-07-31 |
2023-01-13 |
|
Humanisoituja vasta-aineita psma:ta vastaan
|
|
JP7548587B2
(ja)
|
2018-09-07 |
2024-09-10 |
アイタブメッド （エイチケイ） リミテッド |
二重特異性抗原結合タンパク質及びその使用
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
JP7612571B2
(ja)
|
2018-10-03 |
2025-01-14 |
ゼンコア インコーポレイテッド |
Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
|
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
MX2021010390A
(es)
|
2019-03-01 |
2021-11-17 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a enpp3 y cd3.
|
|
JOP20210253A1
(ar)
|
2019-04-05 |
2023-01-30 |
Teneobio Inc |
أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma
|
|
AR118721A1
(es)
*
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer renal con un anticuerpo anti-psma / cd3
|
|
MA55717A
(fr)
*
|
2019-04-19 |
2022-02-23 |
Janssen Biotech Inc |
Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
|
|
MX2021014007A
(es)
|
2019-05-14 |
2022-01-24 |
Harpoon Therapeutics Inc |
Proteinas de union a epcam y metodos de uso.
|
|
CU20210096A7
(es)
|
2019-05-21 |
2022-06-06 |
Novartis Ag |
Moléculas de unión a cd19
|
|
AR119746A1
(es)
|
2019-06-14 |
2022-01-05 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
WO2021006199A1
(ja)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
KR20220083667A
(ko)
*
|
2019-07-26 |
2022-06-20 |
익사카 프랑스 |
압타머 기반의 다중특이 치료제
|
|
US12441807B2
(en)
|
2019-09-18 |
2025-10-14 |
Lamkap Bio Alpha AG |
Bispecific antibodies against CEACAM5 and CD3
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
EP3842461A1
(en)
|
2019-12-23 |
2021-06-30 |
Albert-Ludwigs-Universität Freiburg |
Chimeric antigen receptors that bind to prostate specific membrane antigen
|
|
US20230151102A1
(en)
|
2020-01-13 |
2023-05-18 |
Aptevo Research And Development Llc |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
BR112022013725A2
(pt)
|
2020-01-13 |
2022-10-11 |
Aptevo Res & Development Llc |
Formulações para agentes terapêuticos proteicos
|
|
IL295448A
(en)
|
2020-02-21 |
2022-10-01 |
Harpoon Therapeutics Inc |
flt3 binding proteins and methods of use
|
|
AU2021263448A1
(en)
|
2020-04-29 |
2022-11-24 |
Teneobio, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
BR112022022800A2
(pt)
|
2020-05-11 |
2022-12-13 |
Janssen Biotech Inc |
Métodos para tratamento de mieloma múltiplo
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
AU2021329378A1
(en)
|
2020-08-19 |
2023-03-23 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
|
JP2023542257A
(ja)
|
2020-09-16 |
2023-10-05 |
アムジェン インコーポレイテッド |
癌の治療のために二重特異性ｔ細胞誘導分子の治療用量を投与する方法
|
|
EP4228694A4
(en)
*
|
2020-10-15 |
2024-12-18 |
Janux Therapeutics, Inc. |
ANTIBODIES DIRECTED AGAINST PSMA AND CD3 AND USES THEREOF
|
|
EP4240770A1
(en)
*
|
2020-11-06 |
2023-09-13 |
Amgen Research (Munich) GmbH |
Polypeptide constructs selectively binding to cldn6 and cd3
|
|
US20240209078A1
(en)
|
2020-11-06 |
2024-06-27 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
MX2023006817A
(es)
|
2020-12-09 |
2023-08-14 |
Janux Therapeutics Inc |
Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
|
|
IL305144A
(en)
|
2021-02-16 |
2023-10-01 |
Janssen Pharmaceutica Nv |
Trispecific antibodies targeting BCMA, GPRC5D and CD3
|
|
IL305736A
(en)
|
2021-03-09 |
2023-11-01 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
EP4314070A1
(en)
|
2021-03-24 |
2024-02-07 |
Janssen Biotech, Inc. |
Trispecific antibody targeting cd79b, cd20, and cd3
|
|
EP4330281A1
(en)
|
2021-04-29 |
2024-03-06 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
|
WO2022234102A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
EP4341291A1
(en)
|
2021-05-21 |
2024-03-27 |
Aptevo Research and Development LLC |
Dosing regimens for protein therapeutics
|
|
CN115536740A
(zh)
*
|
2021-06-30 |
2022-12-30 |
苏州方德门达新药开发有限公司 |
介导细胞内有效滞留cd3的空间构象表位及其应用
|
|
JP7707822B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707835B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707836B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707823B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707830B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707828B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707824B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707829B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707821B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707827B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707820B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707834B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707833B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707831B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707832B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707825B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
AU2022380722A1
(en)
|
2021-11-03 |
2024-06-20 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
|
EP4496814A1
(en)
|
2022-03-21 |
2025-01-29 |
Amgen Inc. |
Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
|
|
KR20250011917A
(ko)
|
2022-05-12 |
2025-01-22 |
암젠 리서치 (뮌헨) 게엠베하 |
증가된 선택성의 다중쇄 다중표적화 이중특이적 항원 결합 분자
|
|
WO2025134050A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
|
|
WO2025134049A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
|